Alexion's Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Shots:
- The approval is based on P-III study results assessing of Ultomiris (IV qw- q8w) vs Soliris in 441 patients who were not treated with inhibitors or Soliris with patiparoxysmal nocturnal hemoglobinuria (PNH)
- The study demonstrated a non-inferiority data showing biosimilarity of Ultomiris to Soliris q2w with safe and well tolerated profile
- Ultomiris (ravulizumab-cwvz) is a mAb- used for targeting C5 protein in immune system and has received its expected PDUFA date 18 Feb- 2019 by the US FDA
Ref: Alexion| Image: Alexion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com